Bayer Stock Holds Its Ground as a Supreme Court Ruling, Trade Investigation, and a Biotech Wager Converge

Bayer's stock barely moves despite acquisitions and regulatory news; Supreme Court glyphosate ruling in late June looms as key catalyst for litigation over 65,000 lawsuits.

Investors in Bayer are exercising patience. The German conglomerate’s share price has barely budged in recent days, closing Friday at €37.81, despite a flurry of corporate and regulatory activity. The stock rose 4.36% over the past week, nudging above its 50-day moving average, but remains roughly 24% below the 52-week high of nearly €50. Over twelve months, the shares have climbed about 43%, though a year-to-date decline of 1.33% shows the momentum has stalled.

The overriding reason for the market’s caution is a single date: late June, when the US Supreme Court is expected to rule in the glyphosate case Durnell. The justices will decide whether a state can hold a company liable for a product that the federal Environmental Protection Agency has already approved. A victory for Bayer would instantly invalidate roughly 65,000 pending lawsuits. A loss would fuel a fresh wave of litigation. A final hearing on a proposed multibillion-dollar settlement in Missouri is scheduled for July 9, adding another legal milestone to the calendar.

Amid the courtroom drama, Bayer has been quietly advancing its pharmaceutical pipeline. On June 17, the company closed the acquisition of Perfuse Therapeutics, paying $300 million upfront and committing up to $2.45 billion in milestone payments. The prize is PER-001, an intravitreal implant in Phase II trials for glaucoma and diabetic retinopathy. Separately, the FDA approved a new low-dose MRI contrast agent called Gadoquatrane, and the European Medicines Agency is reviewing Asundexian as a potential stroke-prevention treatment.

Not all operational news is smooth. Bayer filed a lawsuit against Johnson & Johnson in February, accusing it of misleading advertising for the prostate cancer drug Erleada. Bayer claims J&J’s assertion that the drug reduces the risk of death by 51% compared with Bayer’s own Nubeqa is based on a flawed retrospective analysis. A US judge rejected Bayer’s bid for a preliminary injunction in April, and the case continues.

On the trade front, the US Trade Representative launched a Section 301 investigation on June 18 into Germany’s pharmaceutical pricing policies, examining whether the rules discriminate against American commerce. As Germany’s largest drugmaker, Bayer is indirectly exposed to the probe.

Meanwhile, big investors are trimming their exposure. Singapore’s sovereign wealth fund cut its stake from 4.17% to 2.90%, and Goldman Sachs reduced its voting rights to 4.84%. The moves contrast with the company’s improving financial fundamentals: free cash flow reached €2.1 billion in fiscal 2025, while net debt fell to €29.8 billion.

In agriculture, Bayer showcased new products at Expoagro 2026 in Argentina, including the “Preceon” low-stature corn system, due for launch this year, and the “PRO Carbono” digital platform connecting about 3,000 producers for regenerative farming.

Looking ahead, the Supreme Court verdict later this month is the immediate catalyst. After that, Bayer’s second-quarter earnings are due on August 4. Together, the two events should determine whether the stock’s recent sideways drift turns into a decisive move.